Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | CPA1 | P15085 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.33 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.33 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.33 |
| ▸ | HTR2B | P41595 | 1/20 | 0.33 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL489097 | 1.00 | RNPEP (0.43) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL1258031 | 1.00 | RNPEP (0.43) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL4885843 | 0.81 | HTT (0.36) | RNPEPSLC7A5ALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL1101398 | 0.80 | EPHX1 (0.39) | ALDH1A1CPA1 | |
| SCHEMBL1101396 | 0.80 | EPHX1 (0.39) | ALDH1A1CPA1 | |
| SCHEMBL6894525 | 0.78 | HTT (0.47) | ALDH1A1SLC1A3SLC1A2TDP1ADRA1A | |
| SCHEMBL4457494 | 0.78 | HTT (0.47) | ALDH1A1SLC1A3SLC1A2TDP1ADRA1A | |
| SCHEMBL28060909 | 0.74 | CPB2 (0.39) | SLC7A5ALDH1A1LMNAKMT2ACACNA2D1 | |
| SCHEMBL233153 | 0.74 | TDP1 (0.40) | ALDH1A1MEN1KMT2ATDP1 | |
| SCHEMBL28060908 | 0.74 | CPB2 (0.39) | SLC7A5ALDH1A1LMNAKMT2ACACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3223613-B1 | 4-FLUORO-THIO-CONTAINING INHIBITORS OF APP2, COMPOSITIONS THEREOF AND METHOD OF USE | SIMMONS WILLIAM H (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-2483246-B1 | PROCESS FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2017-11-15 | — | — | EP | disclosed |
| EP-3223613-A1 | 4-FLUORO-THIO-CONTAINING INHIBITORS OF APP2, COMPOSITIONS THEREOF AND METHOD OF USE | Simmons, William H. (US) | 2017-10-04 | — | — | EP | disclosed |
| CN-105837511-A | METHOD FOR PREPARING BIPHENYL IMIDAZOLE COMPOUNDS | 施万生物制药研发IP有限责任公司 | 2016-08-10 | — | — | CN | disclosed |
| WO-2016085530-A1 | 4-FLUORO-THIO-CONTAINING INHIBITORS OF APP2, COMPOSITIONS THEREOF AND METHOD OF USE | SIMMONS WILLIAM H (US) | 2016-06-02 | — | — | WO | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9273008-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2016-03-01 | — | — | US | disclosed |
| US-9221763-B2 | Process for preparing biphenyl imidazole compounds | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2015-12-29 | — | — | US | disclosed |
| US-5670699-A | Process for preparing amino acid esters useful as intermediates for compounds containing a fused bicyclic ring | BRISTOL-MYERS SQUIBB CO. (US) | 1997-09-23 | — | — | US | disclosed |
| US-5654294-A | CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB (US) | 1997-08-05 | — | — | US | disclosed |
| EP-0783002-A2 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1997-07-09 | — | — | EP | disclosed |
| US-5646276-A | ANGIOTENSIN CONVERTING ENZYME AND NEUTRAL ENDOPEPTIDASE INHIBITORS; CARDIOVASCULAR DISORDERS | BRISTOL-MYERS SQUIBB CO. (US) | 1997-07-08 | — | — | US | disclosed |
| US-5627278-A | MULTISTAGE REACTION FORMED BY AMIDATION, COUPLING AND REDUCTION | BRISTOL-MYERS SQUIBB CO. (US) | 1997-05-06 | — | — | US | disclosed |
| US-5616775-A | ESTERIFYING A N-PROTECTED METHIONINE; OXIDIZING; REACTING WITH AN ACID ANHYDRIDE THEN AN ALKALI METAL HYDROXIDE | BRISTOL-MYERS SQUIBB CO. (US) | 1997-04-01 | — | — | US | disclosed |
| US-5552397-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5508272-A | SELECTIVE ACE INHIBITORS, HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-04-16 | — | — | US | disclosed |
| EP-0629627-A2 | Bicyclic carboxylic acids and their derivatives as nep and aca inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1994-12-21 | — | — | EP | disclosed |
| EP-0599444-A1 | Dual action inhibitors | E.R. SQUIBB & SONS, INC. (US) | 1994-06-01 | — | — | EP | disclosed |